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OBJECTIVES The purpose of this study was to assess the value of preoperative cardiac testing in
intermediate-risk patients receiving beta-blocker therapy with tight heart rate (HR) control
scheduled for major vascular surgery.
BACKGROUND Treatment guidelines of the American College of Cardiology/American Heart Association
recommend cardiac testing in these patients to identify subjects at increased risk. This policy
delays surgery, even though test results might be redundant and beta-blockers with tight HR
control provide sufficient myocardial protection. Furthermore, the benefit of revascularization
in high-risk patients is ill-defined.
METHODS All 1,476 screened patients were stratified into low-risk (0 risk factors), intermediate-risk (1
to 2 risk factors), and high-risk (3 risk factors). All patients received beta-blockers. The 770
intermediate-risk patients were randomly assigned to cardiac stress-testing (n  386) or no
testing. Test results influenced management. In patients with ischemia, physicians aimed to
control HR below the ischemic threshold. Those with extensive stress-induced ischemia were
considered for revascularization. The primary end point was cardiac death or myocardial
infarction at 30-days after surgery.
RESULTS Testing showed no ischemia in 287 patients (74%); limited ischemia in 65 patients (17%), and
extensive ischemia in 34 patients (8.8%). Of 34 patients with extensive ischemia, revascular-
ization before surgery was feasible in 12 patients (35%). Patients assigned to no testing had
similar incidence of the primary end point as those assigned to testing (1.8% vs. 2.3%; odds
ratio [OR] 0.78; 95% confidence interval [CI] 0.28 to 2.1; p  0.62). The strategy of no
testing brought surgery almost 3 weeks forward. Regardless of allocated strategy, patients with
a HR 65 beats/min had lower risk than the remaining patients (1.3% vs. 5.2%; OR 0.24;
95% CI 0.09 to 0.66; p  0.003).
CONCLUSIONS Cardiac testing can safely be omitted in intermediate-risk patients, provided that beta-
blockers aiming at tight HR control are prescribed. (J Am Coll Cardiol 2006;48:964–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.059© 2006 by the American College of Cardiology Foundation
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cccording to the guidelines of the American College of
ardiology /American Heart Association (ACC/AHA), all
atients scheduled for major vascular surgery who have
See page 970
linical features associated with increased cardiac risk should
ndergo noninvasive cardiac stress-testing (1). Perioperative
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Manuscript received January 27, 2006; revised manuscript received March 7, 2006,
ccepted March 17, 2006.eta-blocker therapy is recommended for patients with
nducible ischemia undergoing major vascular surgery. The
uidelines also recommend coronary angiography for pa-
ients with high-risk noninvasive test results and myocardial
evascularization in patients with prognostic high-risk anat-
my in whom long-term outcome is likely to be improved.
owever, noninvasive testing might delay surgery and run
he risk of aortic aneurysmal rupture or exacerbation of
ritical limb ischemia. Furthermore, a recent randomized,
ontrolled trial of preoperative myocardial revascularization
n vascular surgery patients showed no improvement in
erioperative or long-term outcome associated with prophy-
actic revascularization (2).
In a previous retrospective observational study of 1,351
atients undergoing major vascular surgery, we found that
ounting clinical risk factors effectively stratified vascular
urgery patients into low-risk (0 risk factors), intermediate-
r
c
o
i
r
e
d
v
m
p
D
E
t
i
t
s
M
S
p
g
w
y
b
e
h
m
a
d
f
L
b
r
c
p
o
s
s
a
p
e
i
d
2

w
r
w
t
i
a
a
c
c
o
i
a
f
M
e
B
w
b
w
d
a
b
T
e
b
w
a
d
T
b
w
b
p
w
H
P
m
a
p
c
p
n
t
b
t
c
e
p
E
c
l
d
t
p
a
965JACC Vol. 48, No. 5, 2006 Poldermans et al.
September 5, 2006:964–9 Preoperative Cardiac Testingisk (1 to 2 risk factors), and high-risk (3 risk factors)
ategories (3). Among patients receiving beta-blockers, peri-
perative cardiac event rates were 0% and 0.9% in low- and
ntermediate-risk patients, respectively. Of all intermediate-
isk patients studied, only a minority (2%) experienced
xtensive stress-induced myocardial ischemia (3). These
ata do not support the routine use of preoperative nonin-
asive testing in intermediate-risk patients, who constitute
ore than 50% of the major vascular surgery population,
rovided that perioperative beta-blockade is employed.
We therefore undertook the second multi-center
ECREASE-II (Dutch Echocardiographic Cardiac Risk
valuation) study to prospectively assess the value of cardiac
esting according to the ACC/AHA guidelines in
ntermediate-risk patients receiving beta-blocker therapy with
ight heart rate (HR) control scheduled for major vascular
urgery.
ETHODS
tudy protocol. Between 2000 and 2005, we enrolled 1,476
atients undergoing elective open abdominal aortic or infrain-
uinal arterial reconstruction at 5 participating centers. Patients
ere screened for the following cardiac risk factors: age over 70
ears, angina pectoris, prior myocardial infarction (MI) on the
asis of history or a finding of pathologic Q waves on
lectrocardiography, compensated congestive heart failure or a
istory of congestive heart failure, drug therapy for diabetes
ellitus, renal dysfunction (serum creatinine 160 mol/l),
nd prior stroke or transient ischemic attack.
On the basis of previous study results, patients were
ivided into 3 groups: 0 risk factors (low-risk), 1 or 2 risk
actors (intermediate-risk), 3 risk factors (high-risk) (3).
ow-risk patients were referred for surgery with beta-
locker therapy without additional testing. Intermediate-
isk patients were randomly (1:1) assigned to preoperative
ardiac stress-testing or no testing. Cardiac testing was
erformed by dobutamine echocardiography or dobutamine
r dipyridamole perfusion scintigraphy, as previously de-
cribed (4,5). Test results were scored by the extent of
tress-induced ischemia with a 16-segment model in dobut-
mine echocardiography and a 6-wall model in stress
erfusion scintigraphy. In addition during dobutamine
chocardiography, the HR at which ischemia occurred (i.e.,
schemic HR threshold) was noted. Limited ischemia was
efined by the presence of 1 to 4 ischemic segments or 1 to
ischemic walls, whereas extensive ischemia was defined by
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
CI  confidence interval
MI  myocardial infarction
OR  odds ratio5 ischemic segments or 3 ischemic walls. Patients oithout ischemia as well as those with limited ischemia were
eferred for surgery with beta-blocker therapy. In patients
ith extensive ischemia, test results were discussed with the
reating physicians and only in those patients in whom the
ndex surgical procedure could be delayed was coronary
ngiography performed and revascularization considered
fter the angiography data were obtained. The type of
oronary revascularization, bypass surgery or percutaneous
oronary intervention, was decided by the treating physicians
n the basis of coronary anatomy and the possible delay of the
ndex surgical procedure. High-risk patients were referred for
dditional cardiac testing. All patients provided written in-
ormed consent, and the study was approved by the Erasmus
edical Center medical ethics committee and local research
thics committees.
eta-blocker therapy. Perioperative beta-blocker therapy
as installed in all patients. Patients receiving chronic
eta-blocker therapy continued their medication. Patients
ithout beta-blockers started with bisoprolol 2.5 mg once/
ay at the screening visit. Beta-blocker dose was adjusted in
ll patients at admission to the hospital and on the day
efore surgery to achieve a resting HR of 60 to 65 beats/min.
he same dose of beta-blockers was continued postoperatively
xcept in patients who were unable to take medication orally or
y nasogastric tube postoperatively. In these patients, the HR
as monitored continuously in the intensive care unit or hourly
t the ward, and intravenous metoprolol was administered at a
ose sufficient to keep the HR between 60 and 65 beats/min.
he HR and blood pressure were measured immediately
efore each scheduled dose of beta-blockers. Beta-blockers
ere withheld if the HR was under 50 beats/min or the systolic
lood pressure was under 100 mm Hg. After discharge,
atients continued beta-blocker therapy and dose adjustments
ere carried out during outpatient visits to achieve a resting
R of 60 to 65 beats/min.
erioperative management. Anesthetic management,
onitoring, surgical technique, and other aspects of perioper-
tive management were at the discretion of the attending
hysician. Results of preoperative testing and coronary revas-
ularization were discussed with the attending physicians. In
atients with limited or extensive ischemia, HR and hemody-
amic management during surgery was implemented to con-
rol HR below the ischemic threshold and otherwise below 65
eats/min. Anticoagulant and antiplatelet therapy were con-
inued for a period of at least 4 weeks after percutaneous
oronary intervention and continued during surgery. Intraop-
rative ischemia was treated at the discretion of attending
hysicians, and additional beta-blockers were permitted.
nd point definition. All patients were monitored for
ardiac events during hospital stay after surgery. Twelve-
ead electrocardiography and serum troponin-T level was
etermined 1, 3, 7, and 30 days after surgery. Additional
ests were performed at the discretion of the attending
hysician. Outpatient follow-up was performed at 30 days if
patient had been discharged from the hospital. At theutpatient clinic all patients were screened at 3-month
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Preoperative Cardiac Testing September 5, 2006:964–9ntervals for cardiac events by clinical history, troponin-T
easurements, and 12-lead electrocardiography recording.
ll data were collected by the participating centers and
valuated in a blinded fashion by members of the adverse-
vents committee. The median follow-up was 2.0 years
25th and 75th percentile: 0.8 and 3.1, respectively).
The primary end point was a composite of cardiac death
nd nonfatal MI at 30 days after surgery. Cardiac death was
efined as a death caused by acute MI, significant cardiac
rrhythmias, or refractory congestive heart failure or as a
eath occurring suddenly without another explanation. A
onfatal MI was defined by both a positive troponin-T level
nd a finding of new Q waves lasting more than 0.03 s on
he electrocardiogram. We also report the incidence of the
omposite end point during long-term follow-up. A non-
atal MI during follow-up was defined by new Q waves
asting more than 0.03 s on the electrocardiogram with or
ithout positive troponin-T level.
ample size. The primary objective of this trial was to
emonstrate that the strategy of no testing is non-inferior to
he strategy of cardiac testing in intermediate-risk patients.
n a previous study we noted a 5% incidence of perioperative
ardiac death or nonfatal MI in intermediate-risk patients
3). We judged that the strategy of no testing is non-inferior
o testing if the difference in primary end point is not more
han 4%. On the basis of these assumptions, a total of 734
atients are needed to demonstrate non-inferiority with an
lpha level of 5% and a power of 80%.
tatistical analysis. Continuous data are presented as me-
ian values and corresponding 25th and 75th percentiles,
hereas dichotomous data are presented as percentages.
ifferences in clinical and surgical characteristics between
atients allocated to no testing or testing were evaluated by
hi-square tests. Differences in the incidence of the primary
nd point were evaluated by a chi-square test. The incidence
f cardiac events over time was further examined by the
aplan-Meier method, whereas a log-rank test was applied
o evaluate differences between the allocated treatment
trategies. Analyses were performed according to the inten-
ion to treat principle. All statistical tests were 2-sided and
p value  0.05 was considered significant.
ESULTS
haracteristics of patients. A total of 1,476 patients were
nrolled and screened for cardiac risk factors, and 354
atients (24%), 770 patients (52%), and 352 patients (23%)
ere classified as low-, intermediate- and high-risk, respec-
ively (Fig. 1). A total of 386 intermediate-risk patients were
ssigned to cardiac testing and 384 patients were assigned to
o testing. There were no differences in the presence of
schemic heart disease (i.e., previous MI and angina pecto-
is) between the 2 groups (Table 1). Testing showed no
schemia in 287 patients (74%); limited ischemia in 65
atients (17%), and extensive ischemia in 34 patients
8.8%). No serious side effects occurred during stress- 3esting. Stress-induced ischemia during dobutamine echocar-
iography was noted in 90 patients. The median HR at which
schemia occurred was 112 beats/min (range 92 to 120 beats/
in). Of 34 patients with extensive stress-induced ischemia,
evascularization before surgery was considered feasible by the
reating physicians in 12 patients (35%), percutaneous inter-
ention in 10 patients, and bypass surgery in 2 patients.
oronary angiography showed 2-vessel disease in 5 patients
42%) and 3-vessel disease in 6 patients (50%). Complete
evascularization was achieved in 6 patients (50%).
The median duration of screening to operation was 53
ays (range 13 to 121 days) in patients assigned to testing
nd 34 days (range 7 to 88 days) in the no-testing group
p  0.001). The HR decreased from a median of 70
eats/min at the screening visit to 60 beats/min before
peration and was similar in both groups (Fig. 2).
erioperative cardiac events. The incidence of the 30-day
nd point in low-, intermediate-, and high-risk patients was
.3%, 2.2%, and 8.5%, respectively (p  0.001) (Table 1).
No difference in 30-day outcome was observed in
ntermediate-risk patients with and without testing, (2.3%
s. 1.8%; odds ratio [OR] 0.78, 95% confidence interval
CI] 0.28 to 2.1) (Table 2). The upper limit of the 95% CI
f the absolute risk difference in favor of cardiac testing was
.2%, indicating non-inferiority of the no-testing strategy
ccording to our pre-specified criteria. The incidence of the
rimary end point in patients without, limited, and exten-
ive ischemia was 0%, 6.2%, and 14.7%, respectively (p 
.001). In intermediate-risk patients with extensive isch-
mia, revascularization did not improve 30-day outcome
25.0% vs. 9.1% events; OR 3.3, 95% CI 0.5 to 24; p 
.32). One patient died after successful revascularization
efore surgery because of a ruptured aortic aneurysm.
ate cardiac events. The incidence of the 3-year end point
n low-, intermediate-, and high-risk patients was 0.7%,
igure 1. Flow chart of the study. Cardiac risk factors included: age over
0 years, angina pectoris, prior myocardial infarction on the basis of history
r a finding of pathologic Q waves on electrocardiography, compensated
ongestive heart failure or a history of congestive heart failure, current
reatment for diabetes mellitus, renal dysfunction (serum creatinine 160
mol/l), and prior stroke or transient ischemic attack. Patients with 1 or 2
ardiac risk factors were randomly (1:1) assigned to cardiac testing or no
esting. Test results were classified as no ischemia, limited ischemia, and
xtensive ischemia. Patients with extensive ischemia were considered for
oronary revascularization..7%, and 14.8%, respectively. No difference in 2-year
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September 5, 2006:964–9 Preoperative Cardiac Testingutcome was observed in intermediate-risk patients with
nd without testing (4.3% vs. 3.1%; p  0.30) (Fig. 3).
R control. The incidence of the 30-day end point
howed a significant correlation with HR control. The study
imed at a HR between 60 and 65 beats/min before surgery,
nd the median HR was 60 beats/min. The HR was below
0 beats/min in 1.7% of the intermediate-risk patients and
ore than 65 beats/min in 16.5% (no difference between
llocated groups). Patients with a HR 65 beats/min had
ower incidence of the primary end point than the remaining
atients (1.3% vs. 5.2%; OR 0.24, 95% CI 0.09 to 0.66; p
.003). The incidence of the primary end point increased by
factor 1.5 (95% CI 1.1 to 2.0; p  0.006) for each 5
eats/min heart-rate increase (Fig. 4).
Table 1. Baseline Characteristics
Characteristic All P
No. of patients 1,
Age (yrs) 67.0 (5
Men (%)
History of diabetes (%)
History of angina pectoris (%)
History of myocardial infarction (%)
History of congestive heart failure (%)
History of cerebrovascular accident (%)
History of renal failure (%)
Statin use (%)
ACE inhibitor use (%)
Aspirin use (%)
Type of surgery
Thoraco-abdominal (%)
Tube graft (%)
Bifurcated graft (%)
Femoro-popliteal (%)
*Cardiac risk factors include: age 70 yrs, angina pectoris
accident, diabetes mellitus, and renal failure (3).
ACE  angiotensin-converting enzyme.igure 2. Heart rate at the screening visit, at the day of hospital admission, and
r no testing (right). Heart rate values are presented as beats/min (bpm).ISCUSSION
n this randomized, multicenter study, we found that
ardiac testing of intermediate-risk patients before major
ascular surgery, as recommended by the guidelines of the
CC/AHA, provided no benefit in patients receiving beta-
locker therapy with tight HR control (1). Cardiac test
esults influenced patients’ management. The treating phy-
icians were aware of the presence of stress-induced myo-
ardial ischemia as well as the HR at which ischemia
ccurred (i.e., ischemic threshold). Physicians were encour-
ged to control HR below the ischemic threshold. Further-
ore, in a selected number of patients with extensive
tress-induced ischemia, preoperative coronary revascular-
ts
Patients With 1 or 2
Cardiac Risk Factors*
Testing No Testing
386 384
3.8) 67.3 (60.9, 73.9) 68.0 (60.9, 73.5)
77.5 72.1
22.3 21.9
67.6 63.8
18.7 15.9
3.9 3.7
16.1 16.7
4.9 6.0
42.8 42.2
31.6 33.1
47.2 44.5
5.2 4.4
15.0 10.7
38.9 34.1
40.9 50.8
cardial infarction, congestive heart failure, cerebrovascularatien
467
9.5, 7
73.3
21.8
55.1
27.0
11.5
19.1
8.5
42.1
32.6
45.3
4.9
12.6
38.1
44.4
, myoimmediately before surgery in patients allocated to cardiac testing (left)
i
t
e
t
i
1
9
b
r
d
2
t
r
d
o
a
o
s
t
M
3
m
d
c
b
o
r
6
b
r
r
p
t
e
a
t
s
(
i
v
h
P
p
f
o
o
s
B
s
o
a
t
a
F
3
a
T
c
s
p
T
A
C
P
P
*
968 Poldermans et al. JACC Vol. 48, No. 5, 2006
Preoperative Cardiac Testing September 5, 2006:964–9zation was performed. According to the present guidelines,
his is thought to be the optimal strategy. However, inter-
stingly, compared with the no-testing population, a reverse
rend in perioperative outcome was observed. An absolute
ncrease in perioperative cardiac death or MI of more than
.2% in patients assigned to no testing can be excluded with
5% certainty. Importantly, the strategy of no testing
rought the operation almost 3 weeks forward.
Although testing identified a minority of intermediate-
isk patients with an increased risk of perioperative cardiac
eath or MI, we considered the overall cardiac event rate of
.2% in this population as sufficiently low to preclude
esting.
Preoperative risk stratification with simple clinical cardiac
isk markers effectively identified patients at low-, interme-
iate, and high-risk with a perioperative cardiac event rate
f 0.3%, 2.2%, and 8.5%, respectively. The absence of the
forementioned cardiac risk factors identified a population
f truly low risk, even in the presence of peripheral athero-
clerotic disease. During long-term follow-up a similar
igure 3. Incidence of cardiac death or myocardial infarction (MI) during
-year follow-up according to the number of cardiac risk factors (left) and
llocated strategy in patients with 1 or 2 cardiac risk factors only (right).
he incidence of cardiac death or MI was associated with the number of
ardiac risk factors at screening (log-rank p  0.001). There was no
able 2. Patient Outcome at 30 Days After Surgery
No. of
Patients
All-Cause
Death (%) p Value
Card
De
ll patients 1,476 51 (3.5) 27
ardiac risk factors 0.002
0 354 6 (1.7) 1
1 or 2 770 23 (3.0) 8
3 352 22 (6.3) 18
atients with 1 or 2 cardiac
risk factors
0.14
Allocated to testing 386 15 (3.9) 6
Allocated to no testing 384 8 (2.1) 2
atients with 1 or 2 cardiac risk
factors allocated to testing
0.001
No ischemia 287 6 (2.1) 0
1–4 ischemic segments 65 3 (4.6) 2
5 ischemic segments 34 6 (17.7) 4
These estimators use a correction of 0.5 in the cell that contains a zero.
CI  confidence interval; MI  myocardial infarction.(
ignificant difference in the long-term incidence of cardiac events between
atients allocated to cardiac testing or no testing (log-rank p  0.30).rend was observed; the incidence of late cardiac death and
I in low-, intermediate-, and high-risk patients was 0.7%,
.7%, and 14.8%, respectively (p   0.001) (Fig. 3).
Beta-blocker therapy has become an essential part of the
edical treatment of patients with acute coronary syn-
romes, also a major cause of perioperative adverse out-
ome. Two randomized trials showed that perioperative
eta-blocker therapy was associated with an improved
utcome in high-risk surgical patients (6,7). A recent large
etrospective observational study, evaluating the effect from
63,635 surgical procedures confirmed the benefit of beta-
locker in those with increased risk (8). These promising
esults were questioned by a recent meta-analysis of 8
andomized clinical trials evaluating a total number of 1,152
atients. This meta-analysis showed only a nominal statis-
ically significant effect of beta-blockers for the composite
nd point of 30-day cardiovascular mortality, nonfatal MI,
nd nonfatal cardiac arrest (relative risk 0.44; 95% CI 0.20
o 0.97) (9). Two more recently completed studies failed to
how a favorable effect of beta-blockers. In the POBBLE
Perioperative Beta-Blockade) trial metoprolol failed to
mprove 30-day cardiovascular outcome in 97 low-risk
ascular surgery patients; those with a history of ischemic
eart disease were excluded (10). The DIPOM (Diabetic
ostoperative Mortality and Morbidity) trial, involving 921
atients with diabetes undergoing non-cardiac surgery,
ailed to show that metoprolol significantly reduced the risk
f death and cardiac complications after a median follow-up
f 18 months (11).
A potential factor that might explain these conflicting
tudy outcomes is a difference in dosing and HR control.
eta-blockers reduce HR and myocardial contractility and,
ubsequently, myocardial oxygen demand. To exert the
ptimal beneficial effect, dose adjustments for HR control
re important. In a small randomized study, the HR
hreshold at which ischemia occurred was assessed with
mbulatory electrocardiographic monitoring in 26 patients
ular
) p Value MI (%)
Cardiovascular
Death or MI (%)
Odds Ratio
(95% CI) p Value
39 (2.6) 48 (3.3)
0.001 0.001
0 (0) 1 (0.3) 1
13 (1.7) 17 (2.2) 8.0 (1.1, 161)
26 (7.4) 30 (8.5) 33 (4.8, )
0.29 0.62
7 (1.8) 9 (2.3) 1
5 (1.3) 7 (1.8) 0.78 (0.28, 2.1)
0.001 0.001
0 (0) 0 (0) 1
4 (6.2) 4 (6.2) 42 (2.2, )*
) 3 (8.8) 5 (14.7) 107 (5.8, )*iovasc
ath (%
(1.8)
(0.3)
(1.0)
(5.1)
(1.6)
(0.5)
(0)
(3.1)
(11.812). These patients were randomized to either tight HR
c
b
T
t
c
c
t
p
n
l
b
S
i
p
p
e
r
s
t
C
l
p
r
p
A
T
o
p
A
m
R
H
3
e
R
1
1
1
A
F
a
F
F ratio
969JACC Vol. 48, No. 5, 2006 Poldermans et al.
September 5, 2006:964–9 Preoperative Cardiac Testingontrol (i.e., 20% less than the ischemic threshold but 60
eats/min) or normal, non-adjusted beta-blocker therapy.
ight HR control was associated with a significant reduc-
ion of perioperative ischemia in 7.7% versus 92%. We
onfirmed these findings, because tight HR control was
learly associated with an improved outcome. We believe
hat for a proper interpretation of the perioperative cardiac
rotective effect of beta-blockers, the effect on HR control
eeds to be taken into account. This might be a potential
imitation for clinical trials using a study design with
linded randomization and fixed beta-blocker doses.
tudy limitations. The assessment of the HR at which
schemia occurred during stress-testing was only feasible in
atients evaluated by dobutamine echocardiography. In
atients evaluated by nuclear imaging only, the presence and
xtent of ischemia could be assessed. The effect of coronary
evascularization in intermediate-risk patients with exten-
ive stress-induced ischemia can not be assessed, owing to
he insufficient number of patients studied.
onclusions. In conclusion, we found that 30-day and
ong-term cardiac death and MI rate in intermediate-risk
atients undergoing abdominal aortic or infrainguinal arte-
ial reconstruction surgery was sufficiently low to preclude
reoperative testing for coronary artery disease.
cknowledgments
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utstanding care of blood sample collections of the study
atients and thank Ian Thomson of the University of
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